Kristie L. Kahl

Articles

Real-World Experience With CAR T Varies From Trials in DLBCL

November 13th 2024

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers

September 16th 2024

AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.

Zipalertinib Demonstrates Safety, Disease Control in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024

Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Pembrolizumab Improves Survival for Gastric/GEJ Adenocarcinoma

September 14th 2024

Pembrolizumab plus trastuzumab and chemotherapy reduced the risk of death by 20% in patients with advanced, unresectable, or metastatic HER2+ gastric or GEJ cancer.

NVL-655 Shows Strong Efficacy in Heavily Pretreated ALK+ NSCLC

September 14th 2024

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC

September 8th 2024

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Camidge and Kahl Reflect on the Impact of Oncology Journalism

July 22nd 2024

Camidge and Kahl reflect on the steps in Kahl’s communications career that paved the way for her to become a leader in the medical journalism field.

Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases

June 3rd 2024

Datopotamab deruxtecan demonstrated comparable intracranial activity and safety in pretreated patients with NSCLC with or without brain metastases.

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

June 2nd 2024

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

Adagrasib Improves Survival, Responses in KRAS G12C+ Advanced NSCLC

June 1st 2024

Compared with standard-of-care chemotherapy, adagrasib significantly improved PFS and tumor responses in KRASG12C-mutated locally advanced or metastatic NSCLC.

ADCs Serve as “Exciting and Effective Drug Delivery System” in HR+/HER2– Breast Cancer

March 8th 2024

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.

Long-Term ADT Plus High-Dose Radiation Provides Survival Advantage in High-Risk Prostate Cancer

January 25th 2024

Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.

Frontline Pembrolizumab Plus Lenvatinib Maintains Efficacy, Shows Promising DOR in Advanced HCC

January 19th 2024

Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.

Financial Navigation Program May Alleviate Cost Burden Associated With Multiple Myeloma

December 12th 2023

Utilization of a financial navigation program is feasible for reducing cost burden and improving quality of life in patients with multiple myeloma who are more likely to experience financial toxicity and have difficulty accessing appropriate resources and support services.

Zanubrutinib Triplet Shows Early Promise in Treatment-Naive TP53-Mutant MCL

December 11th 2023

The combination comprised of zanubrutinib, obinutuzumab, and venetoclax elicited high response rates and 2-year progression-free survival rates that compared favorably with historical outcomes achieved with chemoimmunotherapy in high-risk patients with previously untreated mantle cell lymphoma harboring TP53 mutations.

Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL

December 11th 2023

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

December 10th 2023

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Zanubrutinib Showcases Sustained PFS Benefit Vs Ibrutinib in R/R CLL/SLL

December 10th 2023

Zanubrutinib continued to demonstrate improved progression-free survival benefit over ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, according to extended follow-up data from the phase 3 ALPINE trial.

Real-World Analysis Sheds Light on Safety and Efficacy of Teclistamab in R/R Multiple Myeloma

December 9th 2023

The T-cell redirecting bispecific antibody teclistamab-cqyv demonstrated efficacy and a tolerable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma consistent with that of those enrolled in the phase 2 MajesTEC-1 trial.

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC

November 11th 2023

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.